Literature DB >> 24529879

Detailed pathologic evaluation on endomyocardial biopsy provides long-term prognostic information in patients with acute myocarditis.

Jong-Chan Youn1, Hyo Sup Shim2, Jae Seok Lee3, Ah-Young Ji1, Jaewon Oh1, Namki Hong1, Hye Sun Lee4, Sungha Park1, Sang-Hak Lee1, Donghoon Choi1, Namsik Chung1, Seok-Min Kang5.   

Abstract

BACKGROUND: The long-term prognosis of biopsy-proven myocarditis is not well known. We hypothesized that a detailed pathological examination of an endomyocardial biopsy (EMB) would reveal prognostic information in patients with acute myocarditis.
METHODS: Fifty-four patients were diagnosed with acute myocarditis based on an EMB. Pathological diagnosis was categorized into lymphocytic dominant (29.6%), eosinophilic dominant (22.2%), and borderline myocarditis (48.1%). Masson's trichrome staining and further immunohistochemical staining for CD3, CD20, CD68, HLA-DR, TLR4, TLR8, enteroviral VP1, and caspase-3 expression were performed. The clinical outcomes were defined as all-cause and cardiovascular (CV) death.
RESULTS: During the median 10.4 years of follow up (9.7±5.7 years), the overall all-cause mortality was 20.4% and the CV mortality was 14.8% in patients with acute myocarditis. Lymphocytic dominant myocarditis patients showed a poor clinical outcome when compared with eosinophilic dominant myocarditis patients for both all-cause (37.5% vs. 0%, p=0.015) and CV (31.2% vs. 0%, p=0.029) mortality. Among borderline myocarditis patients, the presence of fibrosis was linked with poor clinical outcomes in both all-cause (75.0% vs. 21.4%, p=0.045) and CV (100.0% vs. 25.0%, p=0.034) mortality. No significant associations between clinical outcome and all other immunohistochemical staining targets were observed.
CONCLUSIONS: Detailed pathological evaluation on an EMB provides prognostic information in patients with acute myocarditis. EMB evaluation should be considered in patients with suspected myocarditis.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Diagnosis; Endomyocardial biopsy; Histopathology; Myocarditis; Prognosis

Mesh:

Substances:

Year:  2014        PMID: 24529879     DOI: 10.1016/j.carpath.2014.01.004

Source DB:  PubMed          Journal:  Cardiovasc Pathol        ISSN: 1054-8807            Impact factor:   2.185


  7 in total

1.  Clinically suspected myocarditis with pseudo-infarct presentation: the role of endomyocardial biopsy.

Authors:  Alida L P Caforio; Giacomo Malipiero; Renzo Marcolongo; Sabino Iliceto
Journal:  J Thorac Dis       Date:  2017-03       Impact factor: 2.895

Review 2.  [Myocarditis in the differential diagnosis of cardiomyopathies. Endomyocardial biopsy or MRI?].

Authors:  C Besler; G Schuler; P Lurz
Journal:  Herz       Date:  2015-06       Impact factor: 1.443

3.  Fast spontaneous recovery from acute necrotizing eosinophilic myopericarditis without need for immunosuppressive therapy: a case report of a 27-year-old male.

Authors:  Michael Kindermann; Nitin Sood; Peter Ehrlich; Karin Klingel
Journal:  Eur Heart J Case Rep       Date:  2020-06-17

4.  Dramatic and early response to low-dose steroid in the treatment of acute eosinophilic myocarditis: a case report.

Authors:  Yu-Wei Chen; Yu-Cheng Chang; Chieh-Shou Su; Wei-Chun Chang; Wen-Lieng Lee; Chih-Hung Lai
Journal:  BMC Cardiovasc Disord       Date:  2017-05-08       Impact factor: 2.298

5.  Clinical predictors of outcome in patients with inflammatory dilated cardiomyopathy.

Authors:  Konstantinos Karatolios; Volker Holzendorf; George Hatzis; Dimitrios Tousoulis; Anette Richter; Bernhard Schieffer; Sabine Pankuweit
Journal:  PLoS One       Date:  2017-12-21       Impact factor: 3.240

6.  Risk factors analysis of prognosis of adult acute severe myocarditis.

Authors:  Qian Zhang; Rui Zhao
Journal:  World J Clin Cases       Date:  2020-11-26       Impact factor: 1.337

7.  Predictors of long-term outcome in patients with biopsy proven inflammatory cardiomyopathy.

Authors:  Ohlow Marc-Alexander; Michel Christoph; Ting-Hui Chen; Schmidt Andreas; Saenger Joerg; Lauer Bernward; Brunelli Michele
Journal:  J Geriatr Cardiol       Date:  2018-05       Impact factor: 3.327

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.